Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Modifi Bio logo — Modifying DNA to Eradicate Cancer

Modifi Bio

Modifying DNA to Eradicate Cancer

Founded 2021 10 employees Seed Total: $13.10M Biotechnology, Health and Wellness

General Information

Company Name Modifi Bio
Founded Year 2021
Employees 10
Industries Biotechnology, Health and Wellness
Funding Stage Seed
Social

Get notified when Modifi Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Modifi Bio

Modifi Bio is a pioneering biotech startup founded in 2021 with the mission of using innovative DNA modification to combat cancer, as encapsulated in their slogan "Modifying DNA to Eradicate Cancer." The company is developing a groundbreaking oncology therapeutics platform that targets DNA defects in various cancer cells, aiming to revolutionize traditional oncology drug development. Their distinctive approach involves irreparably modifying tumor DNA while sparing healthy cells, achieved through a new class of small molecules directly targeting DNA, sidestepping the need to engage protein targets. This strategy has been successfully tested on a wide range of tumor types in both controlled environments and living organisms, affirming its promise. The founding team comprises esteemed scientists, clinicians, and biotech entrepreneurs. Their core technology, jointly discovered by Seth Herzon and Ranjit Bindra, brings in-depth expertise in synthetic chemistry, DNA repair, and translational research in oncology. Situated at the heart of New Haven, CT’s burgeoning biotech hub, Modifi Bio operates within the Elm City BioScience Center, a cutting-edge facility designed to support emerging biotechnology companies, conveniently located near the Yale School of Medicine. Notably, the startup recently secured a $4.30M seed round investment on 16 October 2023, with significant contributions from Connecticut Innovations, HighCape Partners, Ironwood Capital Connecticut, Pathway Bioventures, National Brain Tumor Society, Sontag Family Trust, and the BrightEdge Fund. This backing underscores investor confidence in Modifi Bio's potential to make a meaningful impact in the biotechnology and health and wellness industries, holding the promise of addressing unmet needs in cancer treatment.

Taxonomy: biotech, oncology therapeutics, DNA modification, cancer treatment, small molecules, tumor DNA repair, biotech hub, Yale University, translational research, New Haven, scientific innovation, startup, clinical research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		16 Oct 2023
Grant •••••• 1 •••• •••• 25 Oct 2022
Seed Round •••••• 2
Investor Investor
28 Jul 2022

FAQ About Modifi Bio

Modifying DNA to Eradicate Cancer
Modifi Bio was founded in 2021.
Modifi Bio operates in the following industries: Biotechnology, Health and Wellness.
Modifi Bio has approximately 10 employees.
Modifi Bio has completed 3 funding rounds, raising a total of $13.10M. The latest funding stage is Seed.

We're actively collecting intelligence on Modifi Bio.

Track Modifi Bio to get notified

Don't just browse. Track.

Signal Tracker monitors Modifi Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes